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Fibrosis is the formation of fibrous connective tissue in response to injury. It is
characterized by the accumulation of extracellular matrix components, particularly
collagen, at the site of injury. Fibrosis is an adaptive response that is a vital component of
wound healing and tissue repair. However, its continued activation is highly detrimental
and a common final pathway of numerous disease states including cardiovascular and
respiratory disease. Worldwide, fibrotic diseases cause over 800,000 deaths per year,
accounting for ∼45% of total deaths. With an aging population, the incidence of fibrotic
disease and subsequently the number of fibrosis-related deaths will rise further. Although,
fibrosis is a well-recognized cause of morbidity and mortality in a range of disease
states, there are currently no viable therapies to reverse the effects of chronic fibrosis.
Numerous predisposing factors contribute to the development of fibrosis. Biological
aging in particular, interferes with repair of damaged tissue, accelerating the transition
to pathological remodeling, rather than a process of resolution and regeneration. When
fibrosis progresses in an uncontrolled manner, it results in the irreversible stiffening of the
affected tissue, which can lead to organ malfunction and death. Further investigation into
the mechanisms of fibrosis is necessary to elucidate novel, much needed, therapeutic
targets. Fibrosis of the heart and lung make up a significant proportion of fibrosis-related
deaths. It has long been established that the heart and lung are functionally and
geographically linked when it comes to health and disease, and thus exploring the
processes and mechanisms that contribute to fibrosis of each organ, the focus of this
review, may help to highlight potential avenues of therapeutic investigation.
Keywords: cardiac fibrosis, pulmonary fibrosis, heart failure, myocardial infarction, idiopathic pulmonary
hypertension, acute respiratory distress syndrome, heart, lung
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INTRODUCTION
The underlying molecular and cellular events of fibrotic diseases
share many functional similarities, despite differences in etiology
and clinical outcome. At its core, chronic fibrosis is pathological
and continuous wound-healing which can effect multiple organ
systems including but not limited to the heart, lung, kidney,
liver, and skin. Although fibrosis is an initially beneficial process
of repair, continuous accumulation of fibrotic proteins leads to
permanent tissue remodeling and significant organ impairment.
The maladaptive response to injury or challenge results in an
excessive accumulation of extracellular matrix (ECM) proteins,
and is mediated by fibroblasts and myofibroblasts. Elements of
the innate and adaptive immune systems also have important
roles, facilitating fibroblast transdifferentiation and ridding the
damaged tissue of apoptotic cells and ECM debris (Zymek
et al., 2006; Wynn and Ramalingam, 2012; Frangogiannis, 2014).
Fibrosis typically presents as interstitial (reactive) or replacement
(reparative) fibrosis. Interstitial fibrosis refers to a chronic and
progressive expansion or scarring of the interstitium as a means
of maintaining organ function. Replacement fibrosis is activated
by an injury, and is a reparative process in which dead cells
are replaced with a collagen based scar (Krenning et al., 2010;
Biernacka and Frangogiannis, 2011; Shinde and Frangogiannis,
2014). Human organ fibrosis has been estimated to contribute
to 45% of all-cause human death, and yet effective treatments
are currently lacking. The molecular events and processes which
contribute to the onset and development of fibrosis must be
elucidated in order to develop novel efficacious treatments.
Given the intimate connection between the heart and lung, this
review will focus on the pathophysiology of fibrosis in these two
organs.
FIBROTIC DISEASE OF THE HEART
Cardiovascular disease (CVD) is the single leading cause of death
worldwide. The World Health Organization estimates that 31%
of all deaths each year are attributed to CVD (17.5 million per
annum; World Health Organization, 2014). Although, the rate of
CVD-related deaths has dramatically declined over the past four
decades (>28%), the burden of disease is still high (Mozaffarian
et al., 2016). The reduced incidence of CVD-related deaths is
largely due to significant risk factor reduction and improved
post-event management. Cardiac fibrosis is implicated in almost
all forms of CVD. Initially cardiac fibrosis is thought to be an
adaptive, protective mechanism, however over time fibrosis leads
to irreversible ventricular remodeling and significantly impaired
Abbreviations: ACE, Angiotensin Converting Enzyme; AEC, Alveolar Epithelial
Cell; AngII, Angiotensin II; ARDS, Acute Respiratory Distress Syndrome;
ATR1, Angiotensin Receptor 1; BALF, Bronchoalveolar Lavage Fluid; CVD,
Cardiovascular Disease; ECM, Extracellular Matrix; FGFs, Fibroblast Growth
Factors; IFN-γ, Interferon-γ; IL, Interleukin; IPF, Idiopathic Pulmonary Fibrosis;
MMPs, Matrix Metalloproteinases; PDGF, Platelet-Derived Growth Factor;
PDGFR, PDGF Receptor; TGF-β, Transforming Growth Factor-β; Th, T helper;
TIMPs, Tissue Inhibitors of Metalloproteinases; TNF-α, Tumor Necrosis Factor-α;
UIP, Usual Interstitial Pneumonia.
heart function. Two common forms of CVD in which fibrosis
plays a major role are myocardial infarction and heart failure.
Myocardial Infarction
Greater than a third of CVD related deaths are attributed to
myocardial infarction. Myocardial infarction is the result of a
blocked coronary artery, and is most common in those aged
over 65 years. Without the capacity for cellular regeneration,
the cardiac tissue must remodel at the cellular level in order
to meet the physiological demands of the system. The signaling
pathways which are activated following myocyte death initiate
acute reparative changes in the heart which can be broken into
initial and late phases. The initial phase involves the replacement
of necrotic tissue with fibrotic scar formation, elongation of
myocytes and thinning of the infarct zone. The volume of the
ventricle increases as an adaptive mechanism to maintain normal
cardiac output and stroke volume (Sutton and Sharpe, 2000;
Konstam et al., 2011). The late phase of ventricular remodeling
involves hypertrophic myocyte elongation in the non-infarcted
areas, increased wall mass, and chamber enlargement. The
ventricle morphologically elongates and the performance begins
to decline. The late phase will progress indefinitely and ultimately
results in heart failure (Konstam et al., 2011). Replacement of
damaged muscle mass with fibrotic tissue is entirely dependent
on the physiological functioning of cardiac fibroblasts (Furtado
et al., 2016).
Heart Failure
Improved medical care has resulted in a larger population
surviving CVD events, and therefore, the prevalence of
secondary complications such as heart failure has increased.
Currently, one in five people globally will develop heart
failure and survival estimates at 5 and 10 years post-diagnosis
are 50 and 10%, respectively (Taylor et al., 2012). Heart
failure is defined by the American Heart Association as “a
complex clinical syndrome that results from any structural
or functional impairment of ventricular filling or ejection of
blood” (Yancy et al., 2013). Heart failure can be broadly
classified as systolic heart failure or diastolic heart failure.
Systolic heart failure is the result of a reduced ejection
fraction and is characterized by reduced efficiency in the
contraction and ejection of blood by the myocardium. Increased
collagen deposition in systolic dysfunction is largely due
to the need for cardiomyocyte replacement after cardiac
damage. This increased ventricular stiffness results in reduced
contraction and cardiac output, and a reduced systemic perfusion
capacity (Khan and Sheppard, 2006). Disruption of myocardial
excitation-contraction coupling, uncoordinated contraction of
cardiomyocyte bundles, disrupted endomysial homeostasis, and
sliding displacement of cardiomyocytes resulting in ventricular
dilation have been proposed as mechanisms of fibrosis-induced
systolic dysfunction (Biernacka and Frangogiannis, 2011). In
diastolic heart failure, the ejection fraction is preserved, however
there is a disturbance in the accommodation of blood volume
during diastole at low filling pressures. Diastolic heart failure
is largely a consequence of impaired ventricular relaxation or
increasedmyocardial stiffness caused by excessive cardiac fibrosis
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(Gomes et al., 2013). The mechanisms underlying diastolic
heart failure involve abnormal ECM composition and cell-ECM
interactions, as well as alterations in the myocyte cytoskeleton,
both of which impair the passive properties of the ventricular wall
(Gomes et al., 2013).
FIBROTIC DISEASE OF THE LUNGS
Fibrosis is also a characteristic of many respiratory diseases that
differ markedly in etiology, phenotype, and symptoms. Fibrosis
can occur in the airway wall, as in the larger airways in asthma
(Boorsma et al., 2014) and around the small airways in chronic
obstructive pulmonary disease (Jones et al., 2016), or the lung
parenchyma, as in idiopathic pulmonary fibrosis (IPF) and acute
respiratory distress syndrome (ARDS). The fibrosis in IPF is
particularly prominent, causing irreversible lung scarring and
respiratory failure (Boorsma et al., 2014; Burnham et al., 2014;
Wuyts et al., 2014).
Idiopathic Pulmonary Fibrosis
Interstitial lung diseases including IPF are characterized by
abnormalities between the capillaries and alveolar spaces of
parenchymal tissue. In IPF, the aberration is a relentlessly
progressive fibrosis that causes irreversible damage to the lung
structure and function (Ryu et al., 2014). Patients with IPF
have a median survival of only 2–5 years from diagnosis. The
prevalence of IPF in the United States is ∼40 cases per 100,000,
and accounts for over 16,000 deaths per year (Lynch et al.,
2016; Raimundo et al., 2016). The health burden of IPF in other
developed and developing countries is no less significant. IPF is
diagnosed primarily in the elderly, and more so in males and/or
patients with a history of smoking (Smith et al., 2013; Wuyts
et al., 2014). Histologically, the spatially heterogeneous pattern
of fibrosis in IPF, referred to as “usual interstitial pneumonia”
(UIP), comprises architectural distortion, interstitial thickening,
presence of fibroblastic foci and honeycombing cystic remodeling
(Rabeyrin et al., 2015). UIP is primarily associated with IPF,
but also occurs in other less common interstitial lung diseases,
including connective tissue-disease associated interstitial lung
diseases and chronic hypersensitivity pneumonitis (Wuyts et al.,
2014). Whilst of unknown etiology (hence the term “idiopathic”),
IPF is now widely considered to be initiated by persistent injuries
to the alveolar epithelium (Selman et al., 2004). Furthermore,
for reasons that remain incompletely understood, the subsequent
injury-repair response to alveolar injury is highly dysregulated,
resulting in the persistence of fibroblasts and the excessive
accumulation of ECM proteins that scar the lung in IPF.
Following an acute exacerbation, IPF patients display additional
damage known as diffuse alveolar damage, which is characterized
by patterns of inter and intra-alveolar accumulation of fibroblasts
and ECM. This additional damage involves regions of lung
previously spared from fibrosis and scarring (Papiris et al., 2010;
Bhatti et al., 2013). Coupled with the existing UIP pattern,
these exacerbations, typically of unknown cause, accelerate the
normally gradual decline of respiratory function into a rapidly
deteriorating state.
Acute Respiratory Distress Syndrome
ARDS is caused by injuries to the alveolar capillary barrier,
comprising an acute inflammation phase and a subsequent
fibroproliferation phase leading to interstitial fibrosis (Frenzel
et al., 2011). ARDS aﬄicts ∼200,000 people annually in the
US, accounting for about 75,000 deaths per annum (Rubenfeld
et al., 2005). ARDS prevalence and mortality increases with
age, and is higher in men than women (Rubenfeld et al., 2005;
Cheifetz, 2016; Cochi et al., 2016). ARDS is initiated by increases
in systemic inflammation of pulmonary or extra-pulmonary
origin. Insults range from direct forms, including viral, fungal, or
bacterial pulmonary infections to indirect forms such as sepsis,
peritonitis, or severe acute pancreatitis (Meduri and Eltorky,
2015). Injury is followed by an acute inflammation phase with
leak of edema fluid into the interstitium and alveoli spaces.
Resolution occurs if the damage from the initial injury is not
severe and ongoing, and when repair processes which restore
alveolar capillary barrier integrity occur in a timely manner. Any
adaptive repair response involves a degree of fibroblast activation
and migration to guide tissue repair by supporting epithelial
and vascular regeneration. However, in many cases of ARDS,
an excessive and persistent fibro-proliferation response occurs
leading to interstitial fibrosis (Frenzel et al., 2011). Mechanical
injury as a consequence of low tidal volume ventilation treatment
strategies heightens the maladaptive fibrotic repair response.
ARDS mortality, which is ∼25% in the US, is strongly associated
with the magnitude of pulmonary fibrosis (Rocco et al., 2009).
Histologically, the pattern of tissue damage in ARDS is referred
to as diffuse alveolar damage, which is differentiated in exudative
and fibro-proliferative phases (Meduri and Eltorky, 2015). The
exudative phase shows spatially uniform alveolar damage, fibrin
deposition (hyaline membranes) along the alveolar wall, lung
edema and hemorrhage. The later phase exhibits patterns of inter
and intra-alveolar accumulation of fibroblasts and ECM.
MOLECULAR AND CELLULAR FIBROTIC
MECHANISMS
Fibroblasts
Fibroblasts are a spindle shaped population of mesenchymal cells
that are found in the connective tissue of most organs (Shinde
and Frangogiannis, 2014). Physiological injury or insult activates
fibroblasts near the site of injury to efficiently undergo dynamic
phenotypic changes that aide in scar formation (Shinde and
Frangogiannis, 2014). Recent data has demonstrated that there
is extensive heterogeneity in fibroblasts from different tissues, as
well as those from the same tissue type (Lajiness and Conway,
2014). Fibroblasts are regarded primarily as the producers of the
ECM, and do so via their extensive endoplasmic reticulum. The
ECM scaffold they produce serves multiple roles including the
support of adjacent cells, cell signaling, and cell adhesion (Hynes,
2009; Frantz et al., 2010; Lajiness and Conway, 2014; Shinde
and Frangogiannis, 2014). Maintaining tissue homeostasis under
normal conditions involves a fine balance in the expression
of the ECM network constituents (Meneghin and Hogaboam,
2007). Under pathological conditions, fibroblast activation and
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proliferation is augmented, leading to increased production of
ECM at the site of injury. Over-production of ECM components
is a commonly observed hallmark of fibrotic diseases, and
ultimately results in a severely scarred, inflexible and functionally
compromised organ.
The origin of fibroblasts in both the heart and lung
remain unclear. In the heart it has been proposed that they
may originate either from local interstitial fibroblasts or from
circulating precursor cells from the bone marrow (Yano et al.,
2005). In the lung, the origins of the fibroblasts may also be
derived from resident interstitial fibroblasts or circulating bone
marrow-derived fibrocytes, or could be derived from epithelial-
mesenchymal transdifferentiation (Mubarak et al., 2012; Maharaj
et al., 2013; Burnham et al., 2014). Aside from epithelial
cells, transdifferentiation of pleural mesothelial cells also
possibly contribute to the increased number of myofibroblasts,
particularly as fibrosis in IPF emanates from the sub-pleura
region (Mubarak et al., 2012). Regardless of source, fibroblasts
contribute to fibrosis by proliferating and differentiating into
collagen producing, contractile myofibroblasts as observed in
cardiac and pulmonary pathologies.
Fibrotic Process in the Heart and Lung
Disease
Myocardial infarction induced fibrosis occurs in three distinct
and controlled phases: the inflammatory, proliferative, and
maturation phases (Zymek et al., 2006; Frangogiannis, 2014;
Table 1). Myocardial necrosis induced by sudden acute death
of cardiomyocytes initiates the inflammatory phase, in which
innate immune pathways are activated, inflammatory mediators
are released, leukocytes are recruited to the infarcted site and
neutrophils are activated (Zymek et al., 2006; Frangogiannis,
2014). The primary inflammatory phase is then actively
suppressed to prepare the site for the proliferative phase. In
this phase, mononuclear cells and macrophage subpopulations
secrete growth factors that recruit and activate reparative
cells including fibroblasts and myofibroblasts (Frangogiannis,
2014). These cells accumulate in granulation tissue, depositing
ECM proteins that contribute to scar formation and preserve
the structural integrity of the tissue (Zymek et al., 2006).
The reparative cells then undergo apoptosis and the wound
transitions into thematuration phase and inflammation begins to
resolve. The resolution of the inflammatory phase results in the
replacement of the vascular granular tissue with a collagen scar
(Zymek et al., 2006; Frangogiannis, 2014). As the scar matures,
significant collagen cross-linking ensues, increasing the tensile
strength of the scar (Czubryt, 2012). This scarring impairs cardiac
contractility and relaxation, leading to ventricular remodeling
and ultimately heart failure, as well as impairments in electrical
signaling synchronicity which can lead to arrhythmogenesis
(Miragoli et al., 2007; Czubryt, 2012). It was long thought that,
unlike other organs, the heart did not contain endogenous stem
cells, and thus, the cells of the heart could not regenerate nor
recellularize after damage, rendering the damage and scarring
irreversible. In 2003, however, a small, yet biologically important
population of endogenous cardiac stem cells were discovered
in rats and subsequently in humans (Beltrami et al., 2003;
Torella et al., 2007). These findings suggested the heart also
has regenerative capacity, albeit limited, and exciting ongoing
research, whilst in its infancy, is exploring the impact on cardiac
fibrosis.
Whilst cardiac fibrosis is largely an adaptive response to
myocyte loss and/or cardiac pressure overload, pulmonary
fibrosis is a response to epithelial injury. The onset and extent
of pulmonary fibrosis depends on the severity and persistence
of the initial injury, as well as the regenerative capacity of
the epithelium. Inadequate re-epithelialization following injury
triggers a cascade of events leading to pathological fibrosis.
Increased type II alveolar epithelial cell (AECII) apoptosis
and senescence are considered to have important roles in the
development of pathological fibrosis in IPF and ARDS (Matute-
Bello et al., 1999; Plataki et al., 2005; Hecker et al., 2014;
Lopez et al., 2015). Following injury, the stages of fibrosis in
cardiac and respiratory disease are similar, as are the cellular
and molecular mechanisms that lead to scar formation. However,
an important difference distinguishing the fibrosis of IPF to
that of many other respiratory and cardiac diseases is the
nature and extent of inflammation. Whilst both the innate and
adaptive immune systems have roles in IPF, the inflammatory
response is far less active than in other forms of fibrosis
(Feghali-Bostwick et al., 2007; Gilani et al., 2010;Margaritopoulos
et al., 2016). As in cardiac fibrosis, pulmonary fibrosis has
consecutive and overlapping fibroproliferative and maturation
stages (Table 1). During these stages, epithelial, endothelial,
and fibroblast cells undergo migration and/or proliferation
in a coordinated process to repair the damaged tissue. The
proliferation and transdifferentiation of fibroblasts leads to an
increase in the myofibroblast population at the site of injury.
These cells facilitate the exaggerated deposition of ECM in
aberrant tissue repair, leading to the formation of an irreversible
scar. As previously outlined, this scar significantly impairs organ
function and ultimately leads to dysfunction and failure. Distinct
from cardiac fibrosis, epithelial cells in IPF and ARDS are a major
source of mediators essential to the migration, proliferation, and
differentiation of resident fibroblasts.
Inflammation
It is well documented that fibrosis is closely linked to
the inflammatory response (Krenning et al., 2010; Biernacka
and Frangogiannis, 2011). Emerging evidence suggests that
cardiac fibrosis in general is primarily due to complications
associated with acute and prolonged inflammation (Biernacka
and Frangogiannis, 2011; Van Linthout et al., 2014), suggesting
that even low-grade, persistent inflammation is enough to
promote cardiac fibrosis. The cellular and molecular events
that underpin the inflammatory processes in cardiac disease are
complex and poorly understood, with many tissue and disease
specific mechanisms. In pulmonary fibrosis however, the role
of inflammation is less clear. Certainly, an active inflammatory
response following injury to the alveolar epithelium contributes
to fibrosis in ARDS. However, the role of inflammation in the
development of IPF pathology is less certain. Whether an initial
injury event(s) and a subsequent acute inflammatory response
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TABLE 1 | Effect of myocardial infarction and idiopathic pulmonary fibrosis on the extracellular matrix in the early and late stages of fibrosis.
Fibrosis Myocardial Infarction Idiopathic Pulmonary Fibrosis
Early fibrosis • Migration of monocytes, macrophages and neutrophils to the infarct zone
• TGF-β stimulated increase in fibroblast chemotaxis




• Expansion of infarct zone
• Increased MMP activity; breakdown of collagen network
• TIMP expression in infarct zone (peaks 48 h post-infarct), allowing
collagen activity
• High Col-III to Col-I ratio
• Increased systolic and diastolic wall stress, wall thinning and ventricular
dilation
• Deformation of border zone and remote zone tissue
• Augmented myocardial shortening and increased heart rate leading to
hyperkinesis (spasm) of non-infarcted myocardium
• Injury to the alveolar epithelium, accompanied by increased epithelial
cell apoptosis and senescence
• Release of inflammatory mediators by epithelial and endothelial cells
• Extravascular hypercoagulation involving activation of coagulant
proteases in association with the formation of a provisional matrix
• Recruitment of neutrophils, macrophages, lymphocytes and
eosinophils to the site of injury
• Cellular inflammation
• Activation and migration of fibroblasts to site of injury
• IncreasedMMP activity; collagen processing andmaturation, localized
collagen denaturation
• High Col-III to Col-I ratio
• Formation of fibrotic foci comprised of a core of fibroblasts surrounded
by hyperplastic or apoptotic/senescent epithelial cells
• Fibrogenesis emanates from sub-pleural regions of the lower lung
Late fibrosis • Continuous LV dilation
• Overall LV remodeling and distorted shape
• Cardiomyocyte hypertrophy (∼70% increase in cell volume)
• Continuing cardiomyocyte necrosis; replacement of myocytes with fibrotic
tissue
• Mural LV wall hypertrophy
• Decreased Col-III and Col-I ratio
• Collagen accumulation (mostly type-III and type-I) in infarct zone
• Scar formation
• Whole LV hypertrophy
• Collagen accumulation (mostly type-III and type-I) in fibrotic lesions
• Heterogeneous architectural distortion
• Lower Col-III to Col-I ratio
• Increased numbers of mast cells, macrophages and lymphocytes
• Increased ECM stiffness leading to a self-perpetuating fibrosis
involving a positive feedback loop
• Bronchiolisation-activation and migration of basal cells in the
conducting airways
• Honeycombing cystic remodeling
• Areas of marked fibrosis and scar formation
Note that the early fibrotic stages of IPF are proposed only, and are still not entirely understood.
occurs is difficult to establish because of the lengthy delay before
the diagnosis of IPF is made (Wuyts et al., 2014). The role
of inflammation in the progression of fibrosis in IPF has been
challenged because anti-inflammatory and immunosuppressive
agents are ineffective as therapies (Davies et al., 2003; Richeldi
et al., 2003). The current prevailing hypothesis is that IPF is
a result of persistent micro-injuries to the alveolar epithelium,
rather than a phenomenon driven by inflammation (Selman
et al., 2004). Despite this conception, there are increased numbers
of inflammatory cells, including mast cells, macrophages, and
lymphocytes in the fibrotic lung and circulation of IPF patients
(Nagai et al., 2007; Peteranderl et al., 2016). Furthermore, the
lung immune cell profiles in IPF and ARDS are similar (Schupp
et al., 2015).
Following cardiac tissue injury, inflammatory and immune
cells such as monocytes, granulocytes, macrophages, mast cells,
dendritic cells, as well as B and T lymphocytes are recruited
to the site of injury. These infiltrating cells are responsible
for producing and secreting an array of both inflammatory
and anti-inflammatory cytokines such as interleukins (e.g., IL-1
and IL-13), tumor necrosis factor-α (TNF-α) and transforming
growth factor-β (TGF-β; Afanasyeva et al., 2004; Blyszczuk
et al., 2008; Kania et al., 2009; Van Linthout et al., 2014).
More recently, these inflammatory cells have been identified to
release fibrogenic cytokines and growth factors which promote
the fibrotic tissue formation following the initial inflammatory
cell infiltrate (Frangogiannis, 2006; Wynn, 2008; Biernacka
and Frangogiannis, 2011). Studies aimed at elucidating the
role of inflammatory cells in the development of cardiac
fibrosis, have focused on the involvement of T helper (Th)
lymphocytes, specifically Th1, Th2, and Th17 lymphocytes (Van
Linthout et al., 2014). Such studies identify that in cardiac
inflammatory wound healing, Th2 lymphocytes act directly and
indirectly (via expression of factors such as IL-4, -5, and -
13) with fibroblasts to promote myofibroblast activation and
suppress matrix metalloproteinase (MMP) activity leading to
the accumulation of ECM proteins and formation of fibrotic
tissue (Yu et al., 2006; Marra et al., 2009; Wei, 2011; Bailey
et al., 2012). Similarly, studies suggest that Th1 lymphocytes
have the ability to play both a pro- and anti-fibrotic role.
The anti-fibrotic role of Th1 lymphocytes has long been
recognized to act via induction of interferon-γ (IFN-γ), which
reduces TGF-β expression (Ulloa et al., 1999; Eickelberg et al.,
2001), and inhibits IL-4 and -13 (Fairweather et al., 2004),
suppressing the formation of fibrotic tissue (Van Linthout et al.,
2014). The pro-fibrotic activity of Th1 lymphocytes is also
achieved via secretion of IFN-γ, which results in production
of pro-fibrotic and pro-inflammatory mediators such as TNF-
α (Nathan et al., 1984; Piguet et al., 1989; Chen et al., 2001;
Marko et al., 2012). Further studies suggest Th1 cells control
activation, migration and differentiation of macrophages, and
macrophage dependent monocyte chemoattractant protein-1
expression, leading to further inflammation and fibrosis (Wynn,
2004; Han et al., 2012; Van Linthout et al., 2014). Finally,
Th17 cells play an essential role in the development of cardiac
fibrosis via the expression of IL-17 (Feng et al., 2009). The
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pro-fibrotic characteristics of IL-17 are derived from its ability
to induce the expression of pro-inflammatory factors, which
in turn, promote the recruitment and activation of neutrophils
(Ouyang et al., 2008; Pelletier et al., 2010), promote MMP-1
expression in cardiac fibroblasts (Cortez et al., 2007), and induce
cardiac fibrosis directly via protein kinase C activation (Liu et al.,
2012).
Interactions between inflammatory cells and resident
structural cells are likely to contribute to pulmonary fibrosis.
Increased numbers of mast cells in the lung of IPF and
ARDS patients elicit fibrogenic actions in a manner involving
direct contact with fibroblasts (Liebler et al., 1998; Wygrecka
et al., 2013). Alternatively activated (M2) macrophages, the
predominant macrophage phenotype in the lungs of IPF
patients, have an impaired innate immune function but produce
fibrogenic mediators such as TGF-β, IL-13, and chemokine
(C-C motif) ligand 18 (CCL18; Pechkovsky et al., 2010). The
latter mediates a fibrogenic axis between M2 macrophages and
fibroblasts in IPF by inducing fibroblast collagen production,
which in turn up-regulates M2 macrophage CCL18 expression
(Prasse et al., 2006; Stahl et al., 2013). Increased numbers of
non-proliferating, antigen-activated T and B cells are also
detected in lung tissue and the circulation of IPF patients
(Daniil et al., 2005; Marchal-Sommé et al., 2006; Kahloon
et al., 2013; Xue et al., 2013). CD8+ T lymphocyte numbers in
particular correlate with measures of respiratory disease severity
in IPF, implicating a role in pulmonary fibrosis (Daniil et al.,
2005). Autoantibodies produced by activated B cells may also
contribute to the development of IPF (Donahoe et al., 2015).
Whilst most autoantibodies are benign, some, such as those
against heat shock protein 70 are pathological (Kahloon et al.,
2013). Therapies that reduce autoantibody production, including
the B cell targeting rituximab, show potential as treatments for
IPF (Donahoe et al., 2015). In lungs of IPF patients, mature
lymphocytes, and dendritic cells form aggregates resembling
lymphoid follicles, which act autonomously to recruit maturing
dendritic cells and recently activated T cells (Marchal-Sommé
et al., 2006). One possible explanation for why IPF is refractory
to anti-inflammatory therapeutics is that these agents primarily
target immature naïve immune cells, not the mature lymphocyte
and dendritic cells detected in IPF.
Pro-Fibrogenic Mediators
Heart
TGF-β has been extensively studied as a mediator of cardiac
fibrosis. The TGF-β signaling cascade is an essential component
of the inflammatory and reparative phases. TGF-β has pleiotropic
effects on cell types important to cardiac injury, repair and
remodeling (Dobaczewski et al., 2011). Latent TGF-β stores exist
in the myocardium for rapid activation following cardiac insult
(Frangogiannis, 2014; Kong et al., 2014). The differentiation
of fibroblasts into myofibroblasts involves the release of TGF-
β, which induces α-smooth muscle actin expression, as well as
the secretion and deposition of ECM proteins and the removal
of the pro-inflammatory mediators which inhibit myofibroblast
conversion. The production of reactive oxygen species, induction
of matricellular proteins and activation of proteases, contribute
to activation of preformed TGF-β at the site of infarction.
Furthermore, platelets, leukocytes and fibroblasts migrate to the
site of cardiac injury and contribute to the increase in TGF-β
levels at the site of injury immediately after infarction. However,
the abundance of circulating pro-inflammatory mediators at
the early stage post-infarction is likely to reduce cellular
responsiveness to TGF-β delaying cellular differentiation to
myofibroblasts and the secretion and deposition of ECM proteins
until the infarct is clear of necrotic cells and matrix debris
conversion (Dobaczewski et al., 2011; Westermann et al., 2011;
Frangogiannis, 2014). Upon completion of the inflammatory
process which clears the infarct, TGF-β signaling is then
able to promote myofibroblast differentiation, thus activating
molecular signaling that releases ECM proteins such as collagen,
and promotes matrix preservation as well as upregulating the
synthesis of protease inhibitors (Frangogiannis, 2014).
Platelet-derived growth factor (PDGF) has a well-established
role in regulating fibrosis and angiogenesis via interactions
with PDGF receptor alpha (PDGFR-α) and beta (PDGFR-β).
Activation of these two receptors induces fibroblast migration,
proliferation and activation (Yu et al., 2001; Raines, 2004). Both
PDGF receptors have been shown to have regulatory roles in
scar formation. For example, over-expression of the PDGFR-α
ligand, PDGF-C, has been shown to induce increased cardiac
fibrosis, collagen deposition, vascular defects, and myocardial
hypertrophy (Ponten et al., 2003). Moreover, overexpression of
the PDGFR-β ligand, PDGF-D, results in cardiac fibrosis followed
by dilated cardiomyopathy and heart failure (Ponten et al., 2003).
PDGFR-β has also been shown to have an additional role in
regulating vascular maturation, by acquiring a mural muscle
coat for the infarct’s micro-vessels (Gerhardt and Betsholtz,
2003; Ponten et al., 2003; Zymek et al., 2006). Furthermore,
genetic disruption of PDGFR-β has been shown to result in
increased microvascular leaks, lethal hemorrhages and edema
in late embryogenesis (Leveen et al., 1994; Zymek et al., 2006).
Inhibition of PDGFR-β activity resulted in impaired vascular
maturation in healing infarcts whereas PDGFR-α inhibition had
no effect on vessel maturation, but significantly reduced the
amount of collagen deposition at the site of infarct (Ponten et al.,
2003; Zymek et al., 2006).
The renin-angiotensin system is another well-established
regulator of cardiac fibrosis (Leask and Abraham, 2004;
Haudek et al., 2010; Frangogiannis, 2014; Kong et al., 2014).
Angiotensin II (AngII) is the primary effector molecule of
renin-angiotensin system and is formed by enzymatic cleavage
of angiotensinogen into angiotensin I by renin, which is
subsequently cleaved into AngII by angiotensin converting
enzyme (ACE; Leask and Abraham, 2004; Haudek et al., 2010;
Kong et al., 2014). Myofibroblasts and inflammatory cells such
as macrophages are known sources of renin and ACE, and
thus are capable of modulating circulating levels of AngII
(Katwa et al., 1997; Haudek et al., 2010). In vitro studies
have demonstrated that AngII can increase fibroblast activation
and proliferation, collagen production and cardiomyocyte
hypertrophy and apoptosis (Sadoshima and Izumo, 1993; Mehta
and Griendling, 2007; Xu et al., 2013; Frangogiannis, 2014).
Furthermore, in vivo rodent studies have demonstrated that
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the intravenous administration of AngII results in significant
myocardial fibrosis, and that serum and tissue levels of AngII
were elevated in animals with pressure-overloaded hearts
(Misaka et al., 2013). Moreover, AngII inhibition using either
ACE inhibitors or AngII type I receptor blockers significantly
improved cardiac function in patients with hypertension as
well as animal models of myocardial infarction remodeling
(Patterson, 2003; Liu et al., 2015). Additionally, the use of
these AngII-inhibiting agents induced the regression of cardiac
remodeling (Figure 1).
Lung
TGF-β is also a central mediator of pulmonary fibrosis. The
expression of TGF-β and/or its receptors are increased in lung
epithelial cells, macrophages and fibroblasts in IPF and non-
resolving ARDS (Khalil et al., 2001; Fahy et al., 2003). Increased
TGF-β affects the alveolar-capillary barrier by disturbing fluid
dynamics and inducing AECII apoptosis. Conversely, TGF-β
inhibits fibroblast apoptosis, a key step in the resolution of
wound repair responses. Furthermore, TGF-β also expands the
mesenchymal compartment by inducing epithelial-mesenchymal
transdifferentiation and fibroblast proliferation, cytokine
production and their differentiation into myofibroblasts. The
genes encoding myofibroblast-associated contractile proteins,
such as α-smooth muscle actin and the ECM molecules, pro-
collagens-I and -III, all contain TGF-β response elements in
their promoters and are regulated by Smad signaling pathways.
In support of its role in pulmonary fibrosis, the selective gene
transfer of TGF-β into AECs induces fibrotic responses ex vivo,
whereas blocking TGF-β-signaling in experimental models of
lung injury attenuates pulmonary edema and fibrosis (Nakao
et al., 1999; Lee et al., 2004; Peters et al., 2014; Dadrich et al., 2016).
In an acute manner, the addition of ectopic TGF-β to alveolar
airspaces in vivo or lung slices ex vivo augments fluid retention by
impairing Na2+ and fluid transport (Peters et al., 2014).
TGF-β is a validated drug target in models of pulmonary
fibrosis. However, the direct targeting of TGF-β or its canonical
Smad signaling pathways is unfeasible as an anti-fibrotic therapy
because of the essential role of TGF-β in immunity and tissue
homeostasis. However, down-stream mediators of TGF-β, or
modifiers of TGF-β effector function, are plausible alternative
therapeutic targets. TGF-β up-regulates the expression of
fibroblast growth factors (FGFs), a family of soluble protein
mediators involved in lung development and tissue homeostasis.
Members of the FGF family, including FGF-1, FGF-2, and FGF-9,
along with their receptors, are increased in fibrotic lung and
implicated in pulmonary fibrosis (Coffey et al., 2013; MacKenzie
et al., 2015). The proliferative effects of TGF-β on pulmonary
fibroblasts are mediated by autocrine actions of FGF (Khalil
et al., 2005). Interestingly, FGF when applied ectopically, can be
protective in experimental pulmonary fibrosis (Fang et al., 2010).
These opposing roles are possibly explained by its dual roles
in epithelial reparation and fibroblast migration/proliferation.
The PDGF family of TGF-β-regulated cytokines are also potent
mitogens, contributing to the expansion of fibroblasts in the
fibro-proliferative phases of IPF and ARDS (Kelly et al., 2003;
Piednoir et al., 2012;Wollin et al., 2015). The expression of PDGF
and its receptors are increased in the epithelium, macrophages
and fibroblasts of fibrotic lung tissue, and targeting PDGF
signaling by either pharmacological or genetic approaches in
experimental fibrosis is protective (Homma et al., 1995; Yoshida
et al., 1999; Dadrich et al., 2016). The efficacy of the FDA-
approved treatment for IPF, nintedanib, is due to its inhibition
of PDGF, FGF and vascular endothelial growth factor-signaling
pathways (Fala, 2015). Connective tissue growth factor is also
a downstream mediator of TGF-β, which has been shown to
mediate fibrosis in several organs, including the heart and lung
(Lipson et al., 2012).
Interactions between the signaling pathways of TGF-β and
AngII (Uhal et al., 2007), amphiregulin (Lee et al., 2014),
wingless/int, or IL-13 (Murray et al., 2008) all contribute
to pulmonary fibrosis. The cross-talk between the TGF-β
and AngII pathways is of particular importance, as they
act synergistically in the development and progression of
pulmonary fibrosis. The role of AngII in pulmonary fibrosis
is evidenced by studies that show ACE inhibitors or AT1R-
selective antagonists attenuate experimental pulmonary fibrosis
(Uhal et al., 2012). Furthermore, polymorphisms in the gene
encoding ACE are associated with IPF and ARDS susceptibility
or outcome (Marshall et al., 2002; Uh et al., 2013). Fibroblasts
and AECs in lung tissue of IPF patients synthesize AngII
de novo, by expressing components of the renin-angiotensin
system, including the AngII precursor, angiotensinogen (Li et al.,
2006). AngII contributes to pulmonary fibrosis by stimulating
pulmonary fibroblast proliferation via angiotensin receptor 1
(ATR1), involving autocrine TGF-β signaling (Marshall et al.,
2000). AngII also induces apoptosis in AECIIs via ATR1
(Papp et al., 2002). The interactions between the AngII and
TGF-β pathways occurs in a reciprocal manner. In pulmonary
fibroblasts, TGF-β is a potent stimulus of angiotensinogen and
ATR1 expression, whereas AngII up-regulates TGF-β expression
(Abdul-Hafez et al., 2009). The synergy between both pathways
suggests that the targeting of AngII synthesis or function is a
potential treatment for IPF (Figure 1).
Regulation of the Extracellular Matrix
In fibrosis, the ECM is substantially thickened by an increase
in the abundance of fibrillar collagens I and III. Fibril
formation is facilitated by increases in fibronectin, a nucleator
of fibrillogenesis (i.e., collagen fibril assembly), whereas collagen
XII and XIV have roles in collagen distribution and organization
(Fukuda et al., 1998). Crosslinking of collagen catalyzed by lysyl
oxidase and glycation contributes to the increased rigidity and
stiffness of fibrotic tissue (Tzortzaki et al., 2006; Barry-Hamilton
et al., 2010). Interestingly, alterations in lysyl oxidase family
members have been linked to IPF (Barry-Hamilton et al., 2010;
Aumiller et al., 2017). Collectively, these biophysical changes to
the ECM in a disease context possibly perpetuate fibrosis as the
proliferative and contractile responses of pulmonary fibroblasts
increase when they are attached to rigid matrices (Marinkovic
et al., 2013; Zhou et al., 2013). Such a detrimental positive
feedback loop involving increased ECM stiffness is thought to
contribute the distinctive expansive pulmonary fibrosis of IPF
(Marinkovic et al., 2013; Zhou et al., 2013).
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FIGURE 1 | Commonly secreted pro-fibrogenic growth factors, inflammatory proteins, matrix metalloproteinases (MMPs), and tissue inhibitors of metalloproteinases
(TIMPs) during the fibrotic processes of myocardial infarction and idiopathic pulmonary fibrosis. Fibrotic disease of the heart and lung is the result of a range of cellular
and molecular responses activated by tissue injury. The fibrotic process is tightly regulated and involves three distinct phases: the inflammatory, proliferative, and
maturation phase. During the inflammatory and proliferative phases, a number of pro-fibrogenic, and inflammatory mediators are released to recruit and activate
reparative mesenchymal cells such as fibroblasts and myofibroblasts. These cells aid scar formation and maintains the structural integrity of the tissue. MMPs and
TIMPs are released by fibroblasts. Their release can be further mediated by various chemokines, cytokines, and growth factors released during the remodeling
process. MMPs and TIMPs work in concert to control the remodeling and degradation of extracellular matrix proteins at the site of injury. ANGII, Angiotensin II; CTGF,
Connective Tissue Growth Factor; FGFs, Fibroblast Growth Factors; PDGF, Platelet-Derived Growth Factor; TGF, Transforming Growth Factor; VEGF, Vascular
Endothelial Growth Factor; IFN-γ, Interferon-γ; IL, Interleukin; TNF, Tumor Necrosis Factor.
Homeostatic balance of the ECM network involves complex
modulation by multiple factors, and includes the ongoing
process of production and deposition of ECM proteins. Two
of the major ECM modulators are localized non-structural
proteins that facilitate the rearrangement of the ECM under
physiological and pathological conditions. These proteins are
the MMPs which degrade ECM proteins and their inhibitors:
tissue inhibitors of metalloproteinases (TIMPs). MMPs and
TIMPs are released throughout the process of tissue healing by
fibroblasts, and they work together to control the remodeling
and degradation of the existing ECM in and around the
site of injury (Fan et al., 2012; Rienks et al., 2014). Several
chemokines, cytokines and growth factors have been shown
capable of regulating the production of MMPs and TIMPs by
fibroblasts. For example, pro-inflammatory cytokines such as
TNFα and IL-1β can induce the transcription of several MMPs
along with TIMP-1 and -2 in the myocardium (Fan et al.,
2012).
MMPs are synthesized and secreted as inactive zymogens
(pro-MMPs) which are activated by removal of an amino-
terminal propeptide domain, which exposes a catalytic domain
(Vanhoutte and Heymans, 2010; Fan et al., 2012). There are
∼26 identified MMPs to date, and of these MMP-1, -2, -3,
-8, -9, -12, -13, and -28 have been implicated in myocardial
remodeling (Fan et al., 2012). MMP-1, -8, and -13 cleave native
(fibrillar) forms of collagen types I, II and III, whereas the
gelatinolytic MMP-2 and -9 cleave collagen types I, IV, and V
(Fan et al., 2012). MMPs are additionally responsible for the
release of growth factors from the ECM, cleavage of receptors
for these growth factors at the cell’s surface and activation
of other MMPs (Vanhoutte and Heymans, 2010). In addition,
the membrane-type MMP (MT1-MMP/MMP14), which cleaves
several ECM proteins, has been highlighted to be of importance
in the heart, as a reduction in MT1-MMP improves survival
and heart function post myocardial infarction in mice, whilst
overexpression lowers survival and function (Zavadzkas et al.,
2011). In IPF and ARDS, the levels of MMP-1, -3 , -7, -8,
-9, -13, and/or -28 in lung tissue are increased, correlating
with disease severity (Selman et al., 2000; Henry et al., 2002;
Fligiel et al., 2006; Craig et al., 2015). Furthermore, several
membrane- type MMPs have been shown to be associated with
IPF. MT1-MMP and MT2-MMP are increased in the lungs
of IPF patients and murine lung fibrosis models, and MT3-
MMP was expressed by fibroblasts and AECs in IPF (Craig
et al., 2015; Pardo et al., 2016). MT6-MMP was also shown to
be decreased in lung tissue of patients with IPF (Pardo et al.,
2016). Other proteases involved in collagen remodeling including
urokinase plasminogen activator and fibroblast activation protein
Frontiers in Physiology | www.frontiersin.org 8 October 2017 | Volume 8 | Article 777
Murtha et al. Cardiac and Pulmonary Fibrosis
α are increased in the lung interstitium of IPF patients (Acharya
et al., 2006; Schuliga et al., 2017). A potential mechanism by
which MMPs and other matrix degrading proteases contribute
to pulmonary fibrosis is by remodeling collagen into forms that
evoke fibrogenic actions. MMP-1, -8, and -13 and fibroblast
activation protein α are collagenolytic enzymes that cleave
and subsequently release native collagen I and III fibrils.
The resulting collagen fragments retain the triple helical
conformation that binds α2β1 integrin on pulmonary fibroblasts
to augment proliferation (Schuliga et al., 2009). Conversely,
native collagen I and III bind α2β1 integrin in a different manner
that suppresses pulmonary fibroblast proliferation (Schuliga
et al., 2009, 2010). The pericellular proteolytic denaturation
of collagen immediately surrounding pulmonary fibroblasts
possibly preserves the proliferative, synthetic phenotype of
fibroblasts with little impact on net tissue stiffness. The spread
of fibrosis from discrete regions of the lower lung, as happens in
IPF, may occur because of pericellular proteolysis at the leading
edge, where fibroblast proliferation is most active (Acharya et al.,
2006; Nkyimbeng et al., 2013). Asides from their direct role
in ECM remodeling, MMPs possibly contribute to fibrosis by
inducing epithelial-mesenchymal transdifferentiation, fibrocyte
infiltration, and the polarization of alveolar macrophages into a
M2 phenotype via activation of fibrogenic cytokines (Craig et al.,
2015).
TIMPs, as their name suggests, inhibit MMP activity
by binding to active sites on their respective MMPs, thus
preventing them from cleaving ECM components (Vanhoutte
and Heymans, 2010). TIMP-2, -3, and -4 are expressed in
the healthy heart, whilst TIMP-1 expression is low, although
it is upregulated under pathological conditions (Fan et al.,
2012). It is becoming increasingly apparent however that TIMPs
have MMP-independent functions including the regulation
of apoptosis, cell survival, growth, migration, differentiation,
angiogenesis, and inflammation (Vanhoutte and Heymans,
2010). Adenovirus-mediated overexpression of TIMP-1, -2, -3, or
-4 in cardiac fibroblasts increases proliferation and myofibroblast
differentiation, whereas TIMP-2 overexpression alone increases
collagen production, and TIMP-3 induces apoptosis (Lovelock
et al., 2005). TIMPs are also important regulators of ECM
turnover in the lung. However, information regarding TIMP
levels and distribution in fibrotic respiratory disease is either
limited or inconsistent. To our knowledge, no study has assessed
TIMP levels in human fibrotic ARDS, besides measurements in
bronchoalveolar lavage fluid (BALF), tracheal aspirates or serum,
none of which accurately reflect tissue levels (Miller et al., 2006).
Initial studies indicated that ECM accumulation in IPF is a
consequence of increased TIMP production and a resulting non-
degrading collagen environment. Immunohistochemical analysis
of lung tissue of IPF patients showed an association between
TIMP-2 antigen and fibroblasts, whereas TIMP-1 antigen was
present in interstitial macrophages and TIMP-3 and -4 antigens
were confined to the epithelium (Selman et al., 2000; Garcia-
Alvarez et al., 2006). Garcia-Alvarez et al. also detected TIMP-3 in
fibrotic regions (including fibroblasts) of IPF lung tissue in situ,
and showed that IPF-derived pulmonary fibroblasts expressed
higher levels of TIMP-1, -2, and -3 in vitro characterized by
compared to fibroblasts characterized by from control donors
(Garcia-Alvarez et al., 2006). However, Nkyimbeng et al. (2013)
recently showed that mRNA and protein levels of TIMPs in
the lung of IPF patients and controls were similar, whereas the
levels of MMP-1, -7, and -13 were higher in IPF. They also
showed that MMP-1 and -13 antigenicity in lung of IPF patients’
in situ overlap with collagenolytic activity in certain regions
of fibrosis, particularly the airways where honeycombing cysts
develop. Based on these findings, the authors suggested that the
levels of TIMPs in regions of IPF lung are inadequate to counter
increased collagenolytic MMP production. However, despite
these local increases in collagenolytic activity, overwhelming
matrix production in IPF results in a net increase in ECM.
Another potentially important role of TIMPs in IPF and ARDS
is the regulation of inflammatory responses that drive fibrosis.
TIMP-3 in particular has important roles in M2 macrophage
polarization in lung injury and disease (Gill et al., 2010,
2013).
CURRENT THERAPIES FOR FIBROSIS
Current treatments for heart failure include administration of
ACE inhibitors, β-blockers and spironolactone, which taken
together, target vasodilatation, heart rate and diuresis. This
standard clinical combination of therapeutics has been shown
to reduce death following heart failure, but does not cure or
reverse it. As it stands, there are currently no viable therapeutic
options for heart failure (Breckenridge, 2010). Traditionally,
cardiac fibrosis has not been a major therapeutic target in
heart disease, however it is now believed that targeted cardiac
fibrosis therapy may reduce the progression of heart failure.
The potential therapeutic benefits of inhibition of the TGF-
β pathway via targeting of Smad transcription factors are
under investigation at varying stages of the scientific process
(Roubille et al., 2014). For example targeting Smad3 has
been shown to exert antifibrotic effects, and does so by
attenuating cardiac remodeling (Bujak et al., 2007). Moreover,
other pathways linked to the TGF-β signaling pathways have
been identified as potential therapeutic targets in a number
of pulmonary fibrotic conditions (Roubille et al., 2014). These
investigations are currently in the early pre-clinical stage, and
thus, therapies for fibrosis attenuation in heart failure are not yet
available.
Until 2014, there was no effective IPF treatment.
Glucocorticoids were used as standard therapy for IPF, but
showed no appreciable effect on clinical outcome (Selman et al.,
2004). Whilst the anti-oxidant, N-acetylcysteine combined
with glucocorticoids decelerates loss of lung function for
IPF patients, there is no effect on mortality rates (Demedts
et al., 2005). However, two relatively recent FDA-approved
therapies, pirfenidone, and nintedanib, reduce the rate of
decline in lung function and increase survival, in some
patients, albeit modestly (King et al., 2014; Richeldi et al.,
2014). The mechanism underlying the anti-fibrogenic and
inflammatory actions of pirfenidone are not well understood,
but are thought to involve suppression of TGF-β and TNF-α
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at the translational level (Nakazato et al., 2002). Nintedanib, a
receptor tyrosine kinase inhibitor, inhibits the actions of FGF,
PDGF and vascular endothelial growth factor (Fala, 2015) with
IC50 values <100 nM. The polypharmacology of nintedanib,
targeting several down-stream signaling cascades involved in
angiogenesis and fibroblast proliferation, differentiation and
collagen production, is likely to contribute to its effectiveness
as an IPF therapy. Whilst the effects of both pirfenidone
and nintedanib are small and with significant side effects,
they do provide clinicians and patients hope that IPF is
treatable. Given the relative success of pirfenidone in IPF,
recent trials have investigated its use in animal models of
cardiac fibrosis. These studies demonstrated a reduction in
ventricular remodeling, and reduced cardiac fibrosis in a canine
and murine model of heart failure, respectively (Lee et al.,
2006; Wang et al., 2013; Yamagami et al., 2015). Clinical trials
for Pirfenidone, however, have yet to be undertaken in human
cardiac disease. Furthermore, a recent clinical trial investigating a
monoclonal antibody, FG-3019, which interferes with the action
of connective tissue growth factor was shown to be safe and
well-tolerated in IPF patients, and demonstrated good outcomes
in pulmonary function and extent of fibrosis (Raghu et al.,
2016). Larger phase two clinical trials are currently underway
(NCT01890265).
The mainstay treatment for ARDS has also been
glucocorticoids. However, whilst glucocorticoids were once
thought to reduce fibroproliferation in ARDS, recent studies
show that they have no effect on mortality rates for patients
who display ongoing ARDS criteria 7 days after injury, although
glucocorticoids improve lung function and shorten time on
mechanical ventilation (Meduri et al., 1994; Hudson and
Hough, 2006). A major negative effect of glucocorticoids
treatment for persistent ARDS is the development of intensive
care unit-acquired weakness (Zorowitz, 2016). However,
the beneficial effects of glucocorticoids on overall clinical
improvement appear to outweigh their harmful neuromuscular
effects which include muscle wasting (Meduri et al., 2016). In
the United States, ARDS mortality, which is closely related
to the degree of fibrosis, was reduced from ∼40 to ∼25%
in 5 years from 2000 (National Heart, Lung, and Blood
Institute Acute Respiratory Distress Syndrome (ARDS) Clinical
Trials Network et al., 2006). This reduction was mainly
a result of mechanical ventilation therapy and improved
management practices, rather than the development of
new drug-interventions. Whilst numerous pharmacological
treatments have been evaluated for ARDS in clinical trials,
none have shown any real measurable therapeutic effect, except
in small subgroups of patients with specific causes of lung
injury.
An exciting advance in the treatment of chronic fibrosis
may be the use of stem and progenitor cell-based therapies in
which substantial pre-clinical, and early phase clinical studies
suggest efficacy in multiple organ systems. Pre-clinical trials
of cell-based therapies in animal models of heart failure
and IPF have demonstrated substantial reductions in fibrotic
tissue in the left ventricle and lungs, respectively, and have
led to several Phase I/II clinical trials (Toonkel et al., 2013;
Le et al., 2017). These studies include the use of bone
marrow, placenta, and adipose tissue derived mesenchymal
stem cells, with one study investigating autologous lung stem
cells (NCT02745184). A 2017 systematic review of autologous
stem cell therapy in ischemic heart disease and heart failure
demonstrated that of the 21 randomized controlled trials
included, mortality was significantly reduced at 12 months
post-treatment (4.8 vs. 15.4% in non-treated) with no major
adverse events (Fisher et al., 2017). Although, fibrosis or
therapeutic mechanisms were not investigated in this review,
preclinical studies suggest that reduction in left ventricular
remodeling could be playing a role. Authors cautioned,
however, that the included studies were small and despite
the promising results, larger clinical studies are needed. The
majority of the pulmonary fibrosis cell-based therapy studies
are still ongoing, however two phase-1 trials have recently
been published and suggest allogeneic placental and bone
marrow derived mesenchymal stem cells were feasible and well
tolerated in IPF patients (Chambers et al., 2014; Glassberg
et al., 2017) and future studies to determine efficacy are
warranted.
SUMMARY
Cardiac and pulmonary fibrosis differ markedly in etiology
and outcome of disease. Such divergences relate to the specific
structure and function of the heart and lungs. However,
many similarities between cardiac and pulmonary fibrosis exist,
including shared biochemical pathways and cellular processes
involving inflammatory cells, fibroblasts and ECM. A mutual
pathological theme for both forms of fibrosis involves the ECM.
In a detrimental feed-forward loop, increased accumulation of
stiffened ECM appears to perpetuate an ongoing fibrogenic
response. In cardiac fibrosis, the adaptive accumulation and
remodeling of fibroblast-derived ECM contributes to pressure
overload, subsequent cardiomyocyte death and the formation
of more ECM as replacement. With the exception of myocyte
participation, a comparable self-perpetuating cycle occurs in
the pulmonary fibrosis of IPF, involving the progressive
accumulation of fibroblasts and ECM. Although, further
investigations are required to fully understand the mechanisms
of chronic fibrosis, given the similarities between cardiac and
pulmonary fibrosis, investigating targets and testing future
treatments in both organs seems justifiable and may lead to
better treatment opportunities for diseases such as CVD and
IPF.
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